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Abstract Disclosures
Background:
Following CHAARTED & STAMPEDE, upfront Docetaxel chemotherapy became standard of care for
metastatic hormone-naïve prostate cancer (mHNPC). We sought to evaluate our experience in the
elderly group of patients (>70 yrs) compared with the non-elderly cohort.
Methods:
A retrospective analysis was undertaken of 38 patients commenced on upfront docetaxel
chemotherapy, from Jan 16 - Jan 17. Patients were strati ed as low (LR) and high risk (HR), as per the
LATITUDE study. Progression was de ned as per PCWG-3 criteria. The progression free survival (PFS)
was calculated as time from start of treatment to date of progression and analysed by Kaplan-Meier
estimates and log-rank test. Rates of febrile neutropenia (FN) were also evaluated.
Results:
The median age was 69 (range: 53-80) yrs, with 50% (19/38) HR patients. The median PFS was 11.5m
for progressors (P; 42%) and not reached for non-progressors (NP; 58%), (p<0.0001). Granulocyte
colony stimulating factor (G-CSF) was used in 13/38 (34%) patients; these did not experience FN. The
overall rate of FN was 20% where G-CSF was not used. Overall 31/38 (81.6%) completed 6 cycles of
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chemotherapy, with 26% requiring dose reductions (Table). Overall, of the 9/16 (56.3%) patients who
progressed within 6m of completing docetaxel, 3 had Cabazitaxel as the next treatment (P: 2/3 (66.7%),
median PFS 6.2m) and 6 had novel androgen receptor targeted therapy (P: 5/6 (83.3%), median PFS
3.3m).
Conclusions:
Upfront docetaxel is reasonably well tolerated in the elderly with comparable median PFS to younger
patients. Use of GCSF signi cantly minimizes the risk of FN in this group and should be considered as
standard of care. In patients who progress within 6m of completing docetaxel, we feel optimal
sequencing to be Cabazitaxel followed by subsequent therapies.
Elderly (%) Non-elderly (%)
N 17 (45) 21 (55)
6 cycles completed 12/17 (70.6) 19/21 (90.5)
High risk 8/17 (47) 11/21 (52.4)
FN rate- GCSF 0/6 (0) 0/7 (0)
FN rate- without GCSF 3/11 (27.2) 2/14 (14.2)
No. of progressors 6/17 (35.3%) 10/21 (47.6)
Median PFS (for progressors) 12.5m 11.5m
